INTRODUCTION
============

Giant axonal neuropathy (GAN) is typically diagnosed as a neurodegenerative disorder because its main phenotype involves progressive deterioration of the peripheral and central nervous systems ([@B1]; [@B2]; [@B39]; [@B22]). The pathological hallmark of GAN in the nervous system is the formation of large aggregates of neuronal intermediate filaments (IFs) such as the type IV neurofilament triplet proteins, which cause the swelling and "giant axons" for which the disease is named ([@B1]). These aggregates are not restricted to neurons, as similar IF aggregates have been reported for type III IFs such as vimentin in fibroblasts, Schwann cells, and endothelial cells and glial fibrillary acid protein in astrocytes ([@B39]; [@B40]; [@B3]). In addition, GAN patients frequently have kinky hair, suggesting that keratins, type I and II IF proteins, are also affected ([@B3]). GAN is caused by mutations in the *GAN* gene encoding gigaxonin, a member of the BTB-Kelch family of E3 ligase adapters known to target proteins for ubiquitination and proteasomal degradation ([@B3]). Gigaxonin binds to the neurofilament triplet proteins vimentin, peripherin, and α-internexin via its Kelch domain ([@B30]; [@B21]) and targets vimentin, peripherin, and neurofilament light chain (NFL) for degradation by the proteasome ([@B30]). Mutations in gigaxonin therefore cause defects in IF protein turnover, frequently leading to their accumulation into large bundles and aggregates ([@B30]; [@B20]).

The dramatic changes in vimentin IF network organization in the fibroblasts obtained from skin biopsies of GAN patients are likely to cause significant alterations in cell physiology, as it is well established that the vimentin cytoskeletal system plays important roles in regulating the shape, motility, and mechanical properties of mesenchymal cells such as fibroblasts ([@B17]; [@B38]; [@B13], [@B12]; [@B32]; [@B35]; [@B28]). With respect to cellular mechanics, recent studies show that vimentin IF networks are major contributors to noncortical cytoplasmic stiffness and represent important factors involved in stabilizing and tethering organelles exposed to random fluctuating forces derived from the activities of molecular motors ([@B13], [@B12]). Furthermore, there is evidence supporting a role for vimentin IF in modulating the distribution of mitochondria ([@B10]; [@B51]; [@B53]) and regulating their motile properties by intermittently anchoring them within the cytoplasm ([@B37]). In light of these findings and the abnormal organization and turnover of vimentin IF in GAN patient fibroblasts, we carried out experiments designed to determine whether there are alterations in the motility and distribution of mitochondria within these cells.

RESULTS
=======

Mitochondria in GAN patient fibroblasts are associated with bundles and aggregates of vimentin IFs
--------------------------------------------------------------------------------------------------

In control human fibroblasts, the vimentin IF network is dispersed throughout much of the cytoplasm of spread cells ([Figure 1A](#F1){ref-type="fig"}). In contrast, GAN patient fibroblasts contain abnormally large aggregates and bundles of vimentin IF ([Figure 1, B--D](#F1){ref-type="fig"}; [@B40]; [@B30]). Typically ∼40% of the GAN patient cells used in this study (GAN-NHS-NS-08; see *Materials and Methods*) have ovoid aggregates frequently located near the nucleus, and \>90% of cells contain numerous thick bundles (*n* = 200; [Figure 1, B--D](#F1){ref-type="fig"}). Note that the formation of vimentin IF bundles and aggregates is not restricted to the mutations found in the GAN cells reported in this study (EXON1c.130C\>T and EXON9c.1420G\>C; see *Materials and Methods*) but also occurs in three other GAN mutant fibroblasts, as we previously showed (p.Glu486Lys in Exon 9 and a 57- to 131-kb microdeletion encompassing exons 3--11; IVS6_1g_a and L510X; S52G and C393X; [@B30]).

![Mitochondria are associated with vimentin IFs. Indirect immunofluorescence with anti-vimentin (VIF), mitochondria stained with MitoTracker Red (Mito), and nucleus stained with Hoechst 33258. (A) Control fibroblasts with typical arrays of vimentin IFs (VIF; green) and containing a normal distribution of mitochondria (Mito; red in the same cell). OL, overlay; blue, nucleus. (B) A GAN fibroblast containing bundles and an ovoid aggregate of vimentin IFs (VIF, green) next to the nucleus (blue); mitochondria in the same cell (Mito, red). Boxed regions in B (OL) are shown at higher magnification to reveal details of mitochondrial association with the aggregate (C) and bundles (D) of vimentin IFs. There are also some mitochondria associated with IFs located between the thicker bundles (D). Confocal images. Scale bars, 10 μm.](608fig1){#F1}

Because vimentin IFs interact with mitochondria in normal fibroblasts ([@B51]; [@B53]; [@B37]), we determined whether these organelles are also associated with the vimentin IF aggregates and bundles in the GAN cells. In normal fibroblasts, mitochondria are dispersed throughout the cytoplasm, and their distribution frequently appears similar to that of the vimentin IF network ([@B51]; [Figure 1A](#F1){ref-type="fig"}). In GAN fibroblasts, mitochondria retain their association with the vimentin IFs comprising the aggregates and bundles ([Figure 1, B--D](#F1){ref-type="fig"}). Confocal images of aggregates show that most mitochondria are associated with the surface of these structures, with some distributed more internally (Supplemental Figure S1). The higher resolution afforded by three-dimensional structured illumination microscopy (3D-SIM) further revealed that IFs are organized into cage-like structures at the surfaces of aggregates with closely associated mitochondria ([Figure 2A](#F2){ref-type="fig"} and Supplemental Figures S1 and S2). Many of the mitochondria not associated with the ovoid aggregates are closely associated with the bundles of vimentin IFs present in the GAN cells ([Figures 1D](#F1){ref-type="fig"} and [2B](#F2){ref-type="fig"}). The association between IFs and mitochondria has been confirmed in GAN cells by electron microscopic observations of bundles ([Figure 2C](#F2){ref-type="fig"}). Previously, we showed electron microscopy that mitochondria were also closely associated with the surface and in some cases the interior of aggregates of vimentin IFs ([@B30]). Note that in control fibroblasts, mitochondria are also frequently seen in close proximity to vimentin IFs (Supplemental Figure S2).

![Superresolution and electron microscopy showing details of the association between mitochondria and vimentin IF aggregates and bundles in GAN fibroblasts. (A) The surface of a vimentin IF aggregate. The boxed area shown at higher magnification reveals a cage-like structure of vimentin IFs (VIF; green) forming meshwork mitochondria (Mito; red). OL, overlay. (B) Vimentin IF bundles; the boxed area shown at higher magnification on the right reveals bundles (VIF; green) and closely associated mitochondria (Mito; red). Images in A and B acquired by 3D-SIM. Scale bar, 500 nm. (C) Electron micrograph showing that many 10-nm-diameter vimentin IFs tightly surround mitochondria. Scale bar, 500 nm.](608fig2){#F2}

The motility of mitochondria is altered in GAN fibroblasts
----------------------------------------------------------

The altered distribution of mitochondria and their close association with vimentin IF aggregates and bundles suggest that their motility might be affected. Therefore we compared the motile properties of mitochondria in GAN and control fibroblasts by time-lapse imaging after staining with MitoTracker Red CMXROS (MitoTracker Red). As expected, numerous mitochondria display anterograde and retrograde translocations as they move from one cytoplasmic region to another in control fibroblasts (Supplemental Movie S1). In contrast, individual mitochondria in GAN fibroblasts exhibit only Brownian-like motions, with no detectable translocations (Supplemental Movie S2). We carried out comparative quantitative analyses of the trajectories of the centroid positions of individual mitochondria. Specifically, we determined the motile properties of 62 mitochondria in time-lapse sequences of five different control fibroblasts and 90 mitochondria in five different GAN fibroblasts ([Figure 3](#F3){ref-type="fig"}; see *Materials and Methods*). The data derived from tracking the trajectories of individual mitochondria show that in control cells, they display typical saltatory motions, frequently moving long distances in the same, a reverse, or a new direction ([Figure 3A](#F3){ref-type="fig"}). In contrast, the mitochondria in GAN fibroblasts exhibit only short excursions ([Figure 3B](#F3){ref-type="fig"}). These differences are further emphasized by measurements of the net displacements of mitochondria in both cell types, which demonstrate \>80% reduction in GAN compared with control fibroblasts ([Figure 3C](#F3){ref-type="fig"}). The results in [Figure 3D](#F3){ref-type="fig"} show that mitochondria are anchored in a manner that restricts their movements such that they cannot engage in long translocations but instead appear to move as if extending from an anchorage site. The results show that the mean total distance traveled by mitochondria in 15 min is significantly less in GAN fibroblasts compared with control fibroblasts (22.9 ± 1 vs. 45.1 ± 6.1 μm, respectively; [Figure 3D](#F3){ref-type="fig"}). Further analyses of the live-cell data in control cells show that mitochondria exhibit high fluctuations in instantaneous velocity, reaching a maximum of 2 μm/s ([Figure 3E](#F3){ref-type="fig"}), whereas the instantaneous velocities in GAN cells are very low and relatively constant ([Figure 3F](#F3){ref-type="fig"}). Similar associations between immotile mitochondria and vimentin IF bundles and aggregates have been detected in two other GAN fibroblasts (one containing mutations EXON4(724C\>T) and R242X and the second containing the mutations IVS6_1g_a and L510X; unpublished data).

![The motility of mitochondria is inhibited in GAN patient fibroblasts. Trajectories of individual mitochondria in control (A) and GAN patient (B) fibroblasts. (C) Box plot of net displacement of mitochondria in control and GAN patient fibroblasts. The box represents the 25th and 75th percentiles, the median is denoted by the horizontal line, the mean is indicated by a small dot, and whiskers indicate SD. (D) Bar graph shows the differences in the total distance traveled by mitochondria in control and GAN patient cells (*p* \< 0.001). (E, F) Instantaneous velocities of individual mitochondria (different colors) were determined in control and GAN patient cells. A total of 90 mitochondria in GAN fibroblasts and 62 mitochondria in control cells were analyzed as described in *Materials and Methods*.](608fig3){#F3}

Another use of MitoTracker Red is to assess the membrane potential of mitochondria, a parameter that has been shown to be affected by vimentin IFs ([@B5]). Therefore we determined the mitochondrial membrane potential in control and GAN fibroblasts stained with MitoTracker Red for 30 min, followed by fixation and quantitative fluorescence intensity measurements (see *Materials and Methods*). The results demonstrate that there is no significant difference in membrane potential between normal and GAN fibroblasts bearing several different gigaxonin mutations (Supplemental Figure S3).

Gigaxonin expression restores the motility of mitochondria in GAN fibroblasts
-----------------------------------------------------------------------------

We previously demonstrated that the expression of wild-type gigaxonin in patient fibroblasts causes the loss of IF aggregates and bundles as vimentin is degraded via proteasomes ([@B30]). Therefore we attempted to rescue the defects in the motile properties of mitochondria by transiently expressing wild-type gigaxonin fused to blue fluorescent protein (BFP-gigaxonin) in GAN fibroblasts. The BFP tag was introduced so that cells expressing gigaxonin could be identified. After 24 h, vimentin IF aggregates and bundles persist in some cells and are frequently associated with BFP-gigaxonin ([Figure 4A](#F4){ref-type="fig"}). In other cells, BFP-gigaxonin is more dispersed, and this coincides with the appearance of smaller vimentin IF aggregates, a reduction in bundles, and a much more dispersed IF network ([Figure 4, B and C](#F4){ref-type="fig"}). We carried out live-cell analyses of the motility of mitochondria in GAN fibroblasts containing the more dispersed pattern of BFP-gigaxonin in transfected cells stained with MitoTracker Red. The results show that BFP-gigaxonin expression restores mitochondrial motility in these GAN cells with respect to net displacements and distance traveled ([Figure 4, D and E](#F4){ref-type="fig"}).

![Expression of gigaxonin rescues the motile properties of mitochondria in GAN patient fibroblasts. (A) BFP-gigaxonin (BFP-Gig; white) tends to concentrate in vimentin IF aggregates and bundles (green) at 24 h after transient transfection and processing for immunofluorescence with anti-vimentin. (B) Another cell (asterisk) in the same preparation containing a smaller aggregate and few if any vimentin IF bundles. Note that only one cell in this field was transfected with BFP-gigaxonin (asterisk), which appears more dispersed in the cytoplasm. There is a small, less intensely stained vimentin IF aggregate (VIF; green) and no obvious vimentin IF bundles similar to those seen in the surrounding, nontransfected cells. (C) Higher-magnification view of the same cells; in the one cell expressing BFP-gigaxonin (asterisk), the brightest BFP fluorescence appears to be associated with the remnant of an aggregate. Scale bar, 10 μm. (D) Control and GAN patient cells overexpressing wild-type gigaxonin. The box represents 25th and 75th percentiles, the median is denoted by the horizontal line, the mean is indicated by small dot, and whiskers indicate SD. (E) Bar graph showing that the total distance traveled by mitochondria in control and gigaxonin-overexpressing GAN patient cells is virtually identical. We analyzed 70 mitochondria (stained with MitoTracker Red) in GAN fibroblasts and 62 in control fibroblasts (see *Materials and Methods*).](608fig4){#F4}

Gigaxonin silencing inhibits the motility of mitochondria in normal fibroblasts
-------------------------------------------------------------------------------

We also determined whether knocking down gigaxonin expression in normal fibroblasts could mimic the organizational changes in vimentin IFs seen in GAN fibroblasts and thereby inhibit mitochondrial motility. To this end, we constructed lentiviral vectors encoding three different short hairpin RNA (shRNA) sequences targeting various regions of human gigaxonin and used to them to transduce normal cells. As a control, we transduced normal cells with scrambled RNA sequences (see *Materials and Methods*). All three silencing vectors reduce gigaxonin levels by \>60% at 72 h after transduction as determined by immunoblotting ([Figure 5A](#F5){ref-type="fig"}). At this time, there are no obvious changes in the organization of vimentin IFs. However, by 18 d, vimentin IF aggregates and bundles can be detected in close association with mitochondria ([Figure 5B](#F5){ref-type="fig"}). These cells were stained with Mito-Tracker Red for live-cell image analysis ([Figure 5, C--H](#F5){ref-type="fig"}; see *Materials and Methods*). These analyses revealed that the translocation of mitochondria is significantly inhibited, as determined by tracking the trajectories of individual mitochondria ([Figure 5](#F5){ref-type="fig"}, C and D). In addition, the net displacement of mitochondria is reduced by \>50% in the silenced cells ([Figure 5E](#F5){ref-type="fig"}), and the total distance traveled decreases significantly (from 32.77 ± 0.69 to 18.44 ± 0.28 μm; *p* \< 0.002; [Figure 5F](#F5){ref-type="fig"}). There is also a dramatic decrease in the instantaneous velocities measured for mitochondria in the silenced cells compared with controls ([Figure 5, G and H](#F5){ref-type="fig"}). Therefore gigaxonin silencing significantly inhibits mitochondrial motility. Note that time-lapse imaging involved the random selection of cells in a silenced population, without knowing whether the selected cells had IF bundles or aggregates.

![Silencing gigaxonin in normal fibroblasts impairs mitochondrial motility. (A) Three different shRNAs caused a reduction in the protein levels of gigaxonin in control fibroblasts, as demonstrated by immunoblotting with anti-gigaxonin at 72 h after silencing (see *Materials and Methods*). (B) Left, silencing gigaxonin for longer periods with shRNA \#3 (up to 18 d) causes vimentin IF aggregation (green). Right, higher-magnification view of the same aggregate showing mitochondria (red; nucleus, blue). Scale bars, 10 μm. Trajectories of individual mitochondria in (C) control (expressing scrambled sequence) and (D) gigaxonin-silenced cells. (E) Box plot of net displacement of mitochondria in control and gigaxonin-silenced (Gigaxonin KD) cells. The box represents 25th and 75th percentiles, the median is denoted by the horizontal line, the mean is indicated by a small dot, and whiskers indicate SD. (F) Bar graph shows that there are significant differences in the total distance traveled by mitochondria in control and gigaxonin-silenced cells (*p* \< 0.002). (G, H) Instantaneous velocities of individual mitochondria in control and gigaxonin-silenced cells (each color represents a different mitochondrion). We analyzed 68 mitochondria (stained with MitoTracker Red) in GAN fibroblasts and 62 in control fibroblasts (see *Materials and Methods*).](608fig5){#F5}

Lysosomal motility is normal in GAN patient fibroblasts
-------------------------------------------------------

Mitochondrial motility is powered by motors moving along microtubule and actin filament tracks ([@B14]; [@B36]; [@B52]; [@B42]; [@B29]). Because the overall patterns of microtubules and actin-containing microfilaments appear normal in GAN fibroblasts, even in regions associated with the IF aggregates ([Figure 6, A--H](#F6){ref-type="fig"}; [@B30]), it is somewhat surprising that mitochondrial motility is so significantly inhibited. Given the normal appearance of microtubules and microfilaments, we determined whether the defective transport of mitochondria reflected more general defects in organelle motility in GAN patient cells. To address this, we assayed the motility of lysosomes, another well-studied membrane-bound organelle known to move along both microtubules and microfilaments ([@B18]; [@B31]; [@B48]; [@B44]). We carried out comparative live-imaging analyses of GAN patient and control fibroblasts stained with LysoTracker Red. The results showed that the motile properties of lysosomes in these two cell types were indistinguishable with respect to trajectories ([Figure 6, I and J](#F6){ref-type="fig"}), net displacements ([Figure 6K](#F6){ref-type="fig"}), total distances traveled ([Figure 6L](#F6){ref-type="fig"}), and instantaneous velocities ([Figure 6, M and N](#F6){ref-type="fig"}, and Supplemental Movie S3; see *Materials and Methods*). These results demonstrate that the inhibition of mitochondrial motility in GAN patient fibroblasts is not due to global alterations in microtubule or microfilament networks but instead is a consequence of the altered organization of vimentin IFs.

![Lysosome motility is normal in GAN patient fibroblasts. (A, B) Double immunofluorescence showing that the overall organization of microtubules (red) appears normal in a GAN fibroblast (vimentin IFs; green). The juxtanuclear aggregate in A is shown at increased magnification, showing that microtubules are in close proximity to the aggregate (E, F). (C, D) The overall distribution of actin (red) appears normal in a GAN fibroblast (vimentin IFs; green). The juxtanuclear aggregate in C is shown at higher magnification to show that actin filaments and stress fibers are also in close proximity to the aggregate (G, H). Images are through-focus confocal stacks. Scale bars, 10 μm. (I, J) Trajectories of individual lysosomes in control and GAN patient fibroblasts show no detectable differences. (K) Box plot of net displacement of mitochondrial motility in control and GAN cells. The box represents 25th and 75th percentiles, the median is denoted by a horizontal line, the mean is indicated by a small dot, and whiskers indicate SD. (L) Bar graph shows the total distance traveled by lysosomes in control and GAN patient cells. (M, N) Instantaneous velocities of individual lysosomes in control and GAN patient cells (different colors represent individual mitochondria). Lysosomes were stained with LysoTracker Red, and their motility was assayed as described in *Materials and Methods*.](608fig6){#F6}

DISCUSSION
==========

In this study, we report a close relationship between mitochondria and the aggregates and bundles of vimentin IFs present in GAN fibroblasts. Of most importance, this close association is correlated with a dramatic decrease in the motility of mitochondria, which behave as if they are tethered or anchored to the IF bundles and aggregates. The coincident changes in IF organization and the positioning and motility of mitochondria detected in GAN cells are likely to reflect alterations in the normal interactions between IFs and these organelles. In normal fibroblasts, the overall distributions of mitochondria and vimentin IFs are very similar ([@B51]). This association is retained in cells treated with colchicine, for which the majority of mitochondria remain associated with the perinuclear vimentin IF aggregate that forms in response to the disassembly of microtubules ([@B10]; [@B51]). In vimentin-null mouse fibroblasts, the rate of mitochondrial movement increases by greater than twice compared with wild-type fibroblasts. When vimentin is expressed in these null cells, there is a return to normal rates of motility ([@B37]). Moreover, when vimentin IF networks in normal mouse fibroblasts are disrupted by a dominant-negative mutant (Vim~1-138~), mitochondrial motility increases by ∼70% ([@B37]). The interactions between IFs and mitochondria appear to involve a subdomain of the non--α−helical N-terminus of vimentin ([@B37]). Whether these interactions are direct or indirect remains to be determined. With respect to this latter possibility, the 1b isoform of plectin, a vimentin IF--binding protein, has been shown to localize to the outer membrane of mitochondria ([@B56]). Thus plectin could link mitochondria to vimentin IFs ([@B37]). Taken together, these results demonstrate that vimentin IFs modulate the normal motility of mitochondria, perhaps by intermittently tethering or anchoring them within different regions of the cytoplasm ([@B37]; [@B13], [@B12]). The latter possibility is further supported by the results of this study demonstrating that the overexpression of wild-type gigaxonin in GAN cells results in the loss of IF bundles and aggregates and the rescue of mitochondrial motility at rates that can be even faster than in control fibroblasts ([Figure 4](#F4){ref-type="fig"}). Conversely, silencing gigaxonin in normal cells recapitulates the disease phenotype: vimentin IFs form bundles and aggregates, and mitochondrial motility is inhibited.

At the present time, we can only speculate about the relationship between defects in the targeting of vimentin subunits for degradation by gigaxonin and the formation of the IF bundles and aggregates. Perhaps in the absence of functional gigaxonin in GAN fibroblasts there is an accumulation of IF protein. Indeed, we previously showed that in some patient fibroblasts, there is an increase in vimentin compared with controls, but this is not a consistent finding, since in cells from other patients, vimentin levels were similar to those in controls ([@B30]). It is also possible that there is an abnormal accumulation of posttranslationally modified vimentin subunits normally destined for degradation. For example, vimentin is an extensively phosphorylated protein, and its state of phosphorylation regulates both its state of polymerization ([@B6]; [@B8]; [@B19]; [@B46]; [@B47]) and its organization with respect to bundling and the formation of juxtanuclear aggregates ([@B25]). It is also possible that one or more of the large number of vimentin phosphorylation sites ([@B19]) provide a signal required for the binding of gigaxonin to vimentin subunits ([@B30]; [@B21]), targeting them for ubiquitination and degradation by the proteasome. In support of this possibility, it has been shown that another type III IF protein, desmin, is initially phosphorylated and then ubiquitinated before its degradation in skeletal muscle ([@B7]). It is also conceivable that the overall deficit in vimentin subunit turnover in GAN fibroblasts causes the accumulation of other phosphorylation sites that regulate the tethering or anchorage of mitochondria to vimentin IF. Of interest, as indicated earlier, the N-terminal non--α-helical domain (residues 2--95) contains a site that is involved in anchoring mitochondria ([@B37]) and is the most extensively phosphorylated subdomain of vimentin, containing at least 20 identified phosphorylation sites ([@B19]).

Another possible explanation for defective mitochondrial motility is that the expression of mutant gigaxonin somehow alters the normal interactions between the motors known to be responsible for mitochondrial motility and the microtubule and microfilament tracks along which they move ([@B43]; [@B24]; [@B29]). However, this does not seem to be the case in this study, since both microtubules and microfilaments appear to be normally organized in GAN cells, and the motility of lysosomes, also known to be transported along microtubules and microfilaments ([@B48]; [@B44]; [@B11]), is indistinguishable between normal and GAN cells.

Because GAN presents primarily as a neurodegenerative disease, it is possible that similar alterations in mitochondrial motility and distribution in neurons involving neuronal IFs could result in a loss of these organelles in synaptic regions and nodes of Ranvier, where they are required for high levels of ATP production, calcium buffering, and signaling ([@B45]). Furthermore, defects in the neural IF system disrupt the motility and distribution of mitochondria in motor neurons derived from either NFL-knockout mice or mice expressing Charcot--Marie--Tooth disease mutations in NFL ([@B54]; [@B9]). Other studies have shown that excess neurofilament heavy chain (NFH) induces neural IF aggregates surrounded by mitochondria that cannot move into neurites ([@B50]). There is also in vitro evidence supporting interactions between mitochondria and neural IFs isolated from spinal cords that appear to be mediated by the non--α-helical tail domain of NFH ([@B55]).

Although our studies focused on fibroblasts obtained from GAN patients, the results reported here provide a framework for understanding the defects in the neurons of patients with GAN and should provide new insights into the ongoing National Institutes of Health gene therapy trial involving the intrathecal injection of a gene transfer vector expressing wild-type gigaxonin (<https://clinicaltrials.gov/ct2/show/study/NCT02362438#contacts>). This possibility is supported by our finding that expression of wild-type gigaxonin not only eliminates IF aggregates and bundles but also rescues mitochondrial motility. Most important, and from a basic science perspective, our results also lend further credence to the roles of the IF cytoskeleton in regulating the motile properties and positioning of mitochondria within cells.

MATERIALS AND METHODS
=====================

Mammalian cell culture
----------------------

BJ-5ta human foreskin fibroblasts (American Type Culture Collection, Manassas, VA) were grown as described ([@B30]) and used as controls in all of our studies. The GAN patient fibroblasts used for all of the quantitative studies of mitochondrial motility described here bear the mutations EXON1c.130C\>T and EXON9c.1420G\>C (cell repository maintained at Columbia University, New York, NY). Preliminary observations of mitochondrial motility were also carried out on two other GAN patient fibroblasts with the mutations EXON4 (724C\>T) and R242X (Columbia University) and IVS6_1g_a and L510X (obtained from R. Van Coster, Ghent University Hospital, Ghent, Belgium; [@B30]). Cells were maintained in MEM with [l]{.smallcaps}-glutamine (Invitrogen, Carlsbad, CA) and supplemented with 10% fetal bovine serum (HyClone, Marlborough, MA), 1% BME vitamin solution (Sigma-Aldrich, St. Louis, MO), 1% nonessential amino acids (Corning, Corning, NY), and 0.5% penicillin/streptomycin. All cell cultures were maintained at 37°C in a humidified CO~2~ incubator.

Antibodies and reagents
-----------------------

Primary antibodies included chicken anti-vimentin (Covance, Dedham, MA), rabbit anti-gigaxonin, and rat anti--α-tubulin (Sigma-Aldrich). Secondary antibodies included Alexa Fluor 488 and Alexa Fluor 633 (Invitrogen). To visualize mitochondria, we used MitoTracker Red CMXROS (MitoTracker Red; Molecular Probes, Eugene, OR); for lysosomes, LysoTracker Red DND-99 (Molecular Probes); and for actin, phalloidin--Alexa 568 (Invitrogen); nuclei were stained with Hoechst 33258 (Invitrogen).

For transient transfection experiments, we used Mirus TransIT-LT1 Transfection Reagent according to the manufacturer's instructions (Mirus Bio, Madison, WI). At 24 h after transfection, cells were processed for immunofluorescence (see later description).

DNA constructs and cell transfection
------------------------------------

Wild-type gigaxonin was cloned into the pTagBFP-C mammalian expression vector as follows. Wild-type gigaxonin was amplified by PCR using primers 5′-GATCCTCGAGCATGGCTAGGGCAGTG-3′ (forward) and 5′-GATCGGATCCACAGGGGAATGA­ACACG-3′ (reverse). The PCR product was then digested with *Xho*I and *Bam*HI and cloned into the pTag-BFP-C vector previously digested with the same restriction enzymes. Control cells were transfected with the empty vector.

Gigaxonin-silenced BJ-5ta cell lines were established using shRNA-encoding oligonucleotides with three targeting sequences against gigaxonin: 1) 5'-GAGTGAGTTCCTCCAGTTA-3'; 2) 5'-AGTGAGTTCCTCCAGTTAA-3'; and 3) 5'-GAGAGAGATCCTGGATTAC-3'. These were cloned into pLKO.1 (Addgene, Cambridge, MA), a lentiviral expression vector. Lentiviruses were produced according to the manufacturer's instructions by cotransfecting lentiviral plasmids, along with the helper plasmids pVSVG and pAX2, into 293FT cells (Invitrogen) using Xfect Transfection Reagent (Clontech, Mountain View, CA). Culture supernatants containing lentivirus particles were collected 48 h later. For lentiviral transductions, target cells were incubated with the viral supernatant supplemented with 8 μg/ml Polybrene (Sigma-Aldrich) for 4--8 h, after which the virus-containing medium was replaced with the growth medium. At 48 h posttransduction, the infected cells were selected by supplementing the cell growth medium with 2 μg/ml puromycin, as previously described ([@B30]). For controls, cells were incubated with viral particles containing scrambled sequences and processed as described.

SDS--PAGE and immunoblotting
----------------------------

Cells grown in 60- or 100-mm culture dishes were lysed in Laemmli sample buffer, and equal amounts of proteins in each lane were separated by SDS--PAGE and immunoblotted as previously described ([@B16], [@B15]).

Immunofluorescence and electron microscopy
------------------------------------------

Cells grown on coverslips were processed for indirect immunofluorescence after fixation in methanol as previously described ([@B41]; [@B57]). In some cases, live cells were incubated with 100 nM MitoTracker Red for 30 min at 37°C before washing with fresh culture medium and immediately fixed. The fixed, immunostained cells were imaged using a Zeiss confocal LSM510 META (Carl Zeiss, Jena, Germany) microscope with oil immersion objective lenses (Plan-Apochromat, 63×, 1.40 numerical aperture \[NA\]; Carl Zeiss). Cells were also imaged using the Nikon N-SIM Structured Illumination Super Resolution Microscope (Nikon, Tokyo, Japan) with an oil immersion objective lens (CFI Apochromat, total internal reflection fluorescence (TIRF), 100×, 1.49 NA; Nikon). Electron microscopy was performed as previously described ([@B49]).

Live-cell imaging
-----------------

GAN-NHS-NS-08 or BJ-5ta cells were plated in 35-cm no. 1.5 glass-bottom dishes (MatTek, Ashland, MA) at 70% confluency. For labeling mitochondria, cells were incubated with 100 nM MitoTracker Red CMXROS for 30 min at 37°C according to the manufacturer's instructions ([@B4]), rinsed with prewarmed medium, and placed on the microscope stage for immediate observation. The motility of mitochondria was determined by time-lapse imaging at 3-s intervals for 15 min. Images were captured using an Andor (Belfast, Northern Ireland) XDI Revolution spinning-disk confocal system mounted on a Nikon Perfect Focus Ti microscope equipped with an Andor iXon electron-multiplying charge-coupled device camera and an oil immersion objective lens (Apochromat, TIRF, 60×, 1.49 NA; Nikon). Cells were maintained at 37°C on the microscope in an Okolab (Burlingame, CA) CO~2~ stage incubator. Lysosomes were visualized after incubation in 75 nM LysoTracker Red DND-99 according to the manufacturers' instructions for 30 min at 37°C, rinsed with prewarmed medium, and immediately analyzed for 15 min as described. Live-imaging analyses were carried out on mitochondria in GAN-NHS-NS-08 and BJ-5ta cells under three experimental conditions: no treatment, overexpression of wild-type gigaxonin, and in cells silenced for gigaxonin expression. In each case, movies were taken of 15--20 cells (both GAN and normal fibroblasts). Specifically, the motility of mitochondria within one randomly chosen cell per coverslip was analyzed. For each condition, five movies were selected for detailed tracking of a total of 60--90 individual mitochondria ([@B33], [@B34]). The selection of which movies to analyze was based on the ability to track mitochondria over the entire time period without complications such as aggregation with other mitochondria, moving out of the plane of focus, and so on. Identical procedures were used to analyze the motility of lysosomes as described in *Results* ([Figure 6](#F6){ref-type="fig"}).

Image processing
----------------

Mitochondria were segmented using Mytoe software ([@B26]). After segmentation, individual mitochondria were selected, and centroid positions were tracked to obtain trajectories using custom-written MATLAB (MathWorks, Natick, MA) codes. Net displacement, total distance traveled, and instantaneous velocities were also quantified both for mitochondria and lysosomes using custom-written MATLAB codes. All data were fitted and plotted in Origin software (OriginLab, Northampton, MA). Similar procedures were used to analyze lysosome motility.

Measurement of mitochondrial membrane potential
-----------------------------------------------

Cells grown on coverslips were incubated in medium with 100 nM MitoTracker Red CMXROS for 30 min at 37°C, rinsed with phosphate-buffered saline (PBS), and fixed at room temperature in 4% paraformaldehyde in PBS for 10 min. The fixed cells were rinsed in PBS and mounted on slides as previously described ([@B30]). For quantification of MitoTracker Red fluorescence intensity, images of labeled cells were processed using Fiji software ([@B58]). The images were converted to 8-bit grayscale, and mitochondria were thresholded with the autothreshold function using the Rényi entropy algorithm ([@B23]). Cells were outlined using Li's minimum cross entropy thresholding method ([@B27]). The fluorescence data are the average fluorescence intensity of mitochondria in the given image minus the background (the average gray level in the cytoplasm outside of mitochondria). The fluorescence intensity measurements were subjected to one-way analysis of variance using Graph-Pad Prism 5 Software (La Jolla, CA). See Supplemental Figure S3.
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